- Home
- PEGA vs EXAS Comparison
PEGA vs EXAS Comparison
Compare PEGA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- EXAS
- Stock Information
- Founded
- PEGA 1983
- EXAS 1995
- Country
- PEGA United States
- EXAS United States
- Employees
- PEGA N/A
- EXAS N/A
- Industry
- PEGA EDP Services
- EXAS Medical Specialities
- Sector
- PEGA Technology
- EXAS Health Care
- Exchange
- PEGA Nasdaq
- EXAS Nasdaq
- Market Cap
- PEGA 8.7B
- EXAS 8.6B
- IPO Year
- PEGA 1996
- EXAS N/A
- Fundamental
- Price
- PEGA $52.93
- EXAS $47.47
- Analyst Decision
- PEGA Buy
- EXAS Strong Buy
- Analyst Count
- PEGA 11
- EXAS 22
- Target Price
- PEGA $60.45
- EXAS $66.43
- AVG Volume (30 Days)
- PEGA 1.5M
- EXAS 4.0M
- Earning Date
- PEGA 07-22-2025
- EXAS 08-06-2025
- Dividend Yield
- PEGA 0.11%
- EXAS N/A
- EPS Growth
- PEGA 61.54
- EXAS N/A
- EPS
- PEGA 1.18
- EXAS N/A
- Revenue
- PEGA $1,676,025,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- PEGA $15.75
- EXAS $14.61
- Revenue Next Year
- PEGA $6.23
- EXAS $12.71
- P/E Ratio
- PEGA $45.01
- EXAS N/A
- Revenue Growth
- PEGA 12.47
- EXAS 12.55
- 52 Week Low
- PEGA $29.84
- EXAS $38.81
- 52 Week High
- PEGA $60.96
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- PEGA 48.57
- EXAS 52.00
- Support Level
- PEGA $50.39
- EXAS $44.90
- Resistance Level
- PEGA $53.75
- EXAS $46.26
- Average True Range (ATR)
- PEGA 2.02
- EXAS 1.88
- MACD
- PEGA -0.36
- EXAS 0.61
- Stochastic Oscillator
- PEGA 37.76
- EXAS 94.03
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.